{"id":25503,"date":"2025-01-11T12:18:39","date_gmt":"2025-01-11T11:18:39","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&#038;p=25503"},"modified":"2026-04-18T10:16:00","modified_gmt":"2026-04-18T08:16:00","slug":"tirzepatide-20-mg-pen","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/product\/tirzepatide-20-mg-pen\/","title":{"rendered":"GLP1+GIP PEN 20 mg."},"content":{"rendered":"<div data-elementor-type=\"product-post\" data-elementor-id=\"25503\" class=\"elementor elementor-25503\" data-elementor-post-type=\"product\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d42a7ce elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"d42a7ce\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4eed13e\" data-id=\"4eed13e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-95f5b18 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"95f5b18\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2 data-start=\"286\" data-end=\"371\">Tirzepatide 20 mg pen - an advanced agonist for metabolic studies<\/h2><h3 data-start=\"373\" data-end=\"410\">What is Tirzepatide 20 mg pen?<\/h3><p data-start=\"412\" data-end=\"811\"><span data-start=\"436\" data-end=\"461\">T<\/span><strong data-start=\"436\" data-end=\"461\">irzepatide 20 mg pen<\/strong> is a synthetic peptide analog designed as a dual agonist of GLP-1R and GIPR receptors. The design of the molecule allows simultaneous activation of two key incretin pathways, making it a <strong data-start=\"665\" data-end=\"690\">tirzepatide 20 mg pen<\/strong> an interesting research model in analyses of energy regulation and integration of hormonal signaling.<\/p><p data-start=\"813\" data-end=\"1141\">Type form <em data-start=\"824\" data-end=\"829\">pen<\/em> reflects the dosing model used in clinical trials and allows analysis of pharmacokinetic parameters and dose-response relationships under controlled laboratory conditions. In the research context <strong data-start=\"1047\" data-end=\"1072\">tirzepatide 20 mg pen<\/strong> represents a variant to assess higher receptor exposure.<\/p><hr data-start=\"1143\" data-end=\"1146\" \/><h2 data-start=\"1148\" data-end=\"1186\">Mechanism of receptor action<\/h2><p data-start=\"1188\" data-end=\"1258\">Tirzepatide 20 mg pen works by simultaneously activating receptors:<\/p><ul data-start=\"1260\" data-end=\"1447\"><li data-start=\"1260\" data-end=\"1343\"><p data-start=\"1262\" data-end=\"1343\"><strong data-start=\"1262\" data-end=\"1272\">GLP-1R<\/strong> - associated with modulation of cAMP signaling and insulinotropic responses,<\/p><\/li><li data-start=\"1344\" data-end=\"1447\"><p data-start=\"1346\" data-end=\"1447\"><strong data-start=\"1346\" data-end=\"1354\">GIPR<\/strong> - involved in the regulation of glucose metabolism and the integration of incretin signaling.<\/p><\/li><\/ul><p data-start=\"1449\" data-end=\"1633\">Dual receptor activation leads to an integrated metabolic response, including modulation of the glucose-insulin axis and effects on mechanisms regulating energy balance.<\/p><p data-start=\"1635\" data-end=\"2045\">Mechanistic reviews have shown that simultaneous activation of GIP and GLP-1 can generate a synergistic effect by potentiating cAMP-dependent signaling and activating Gs protein. Molecular studies observed a pronounced dose-dependent effect and intensification of GPCR signaling with increased exposure, making the <strong data-start=\"1965\" data-end=\"1990\">tirzepatide 20 mg pen<\/strong> a useful tool in pharmacodynamic analyses.<\/p><hr data-start=\"2047\" data-end=\"2050\" \/><h2 data-start=\"2052\" data-end=\"2109\">Relevance in clinical and preclinical studies<\/h2><p data-start=\"2111\" data-end=\"2410\">The SURPASS and SURMOUNT study programs analyzed the effects of tirzepatydu on metabolic parameters at long-term follow-up. In the SURMOUNT-1 study (72 weeks), a mean weight reduction of 20.9% and a clear dose-response relationship were reported for the highest doses analyzed.<\/p><p data-start=\"2412\" data-end=\"2570\">SURPASS-2 showed greater reductions in HbA1c compared to a selective GLP-1 agonist, confirming the importance of dual receptor agonism.<\/p><p data-start=\"2572\" data-end=\"2887\">In preclinical studies, dual GIP\/GLP-1 agonism has been analyzed as a model of receptor synergy to study the integration of cAMP pathways and their effects on lipid and carbohydrate metabolism. In this context <strong data-start=\"2786\" data-end=\"2811\">tirzepatide 20 mg pen<\/strong> provides a variant to assess the intensification of the receptor response.<\/p><hr data-start=\"2047\" data-end=\"2050\" \/><h2 data-start=\"2746\" data-end=\"2808\">Tirzepatide 20 mg pen versus other incretin agonists<\/h2><p data-start=\"2810\" data-end=\"2832\">In receptor terms:<\/p><ul data-start=\"2834\" data-end=\"3008\"><li data-start=\"2834\" data-end=\"2876\"><p data-start=\"2836\" data-end=\"2876\">Semaglutide only activates GLP-1R,<\/p><\/li><li data-start=\"2877\" data-end=\"2946\"><p data-start=\"2879\" data-end=\"2946\">tirzepatide (including tirzepatide 20 mg pen) activates GLP-1R and GIPR,<\/p><\/li><li data-start=\"2947\" data-end=\"3008\"><p data-start=\"2949\" data-end=\"3008\">retatrutide additionally involves the glucagon receptor (GCGR).<\/p><\/li><\/ul><p data-start=\"3010\" data-end=\"3170\">The range of activated receptors determines the complexity of the metabolic response and is a key element in differentiating molecules in pharmacodynamic analyses.<\/p><h2 data-start=\"210\" data-end=\"285\">\u00a0<\/h2><hr data-start=\"2047\" data-end=\"2050\" \/><p data-start=\"3225\" data-end=\"3637\"><a href=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-32391 size-medium\" src=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-300x225.png\" alt=\"Tirzepatide 20 mg pen \u2013 dual incretin receptor agonist for metabolic studies\" width=\"300\" height=\"225\" srcset=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-300x225.png 300w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-400x300.png 400w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-800x600.png 800w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-64x48.png 64w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-768x576.png 768w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen-16x12.png 16w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/11\/Tirzepatide-20-mg-pen.png 1024w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p><p data-start=\"3225\" data-end=\"3637\">Sources:<\/p><p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10159347\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10159347<\/a><\/p><p data-start=\"3225\" data-end=\"3637\"><a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23850282\/\" target=\"_new\" rel=\"noopener\" data-start=\"4739\" data-end=\"4780\">https:\/\/pubmed.ncbi.nlm.nih.gov\/23850282\/<\/a><\/p><hr data-start=\"2047\" data-end=\"2050\" \/><p data-start=\"3225\" data-end=\"3637\"><strong>Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p><strong data-start=\"123\" data-end=\"148\">Tirzepatide 20 mg pen<\/strong> is an advanced synthetic peptide with dual activity against GLP-1R and GIPR receptors, which is the subject of intensive research on metabolic regulation, energy balance control and body weight.<\/p>","protected":false},"featured_media":30662,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[122,111,15],"product_tag":[],"class_list":{"0":"post-25503","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-produkty-w-penie","7":"product_cat-glp1gip","8":"product_cat-laboratory-research","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-simple"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/25503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/comments?post=25503"}],"version-history":[{"count":14,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/25503\/revisions"}],"predecessor-version":[{"id":35455,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/25503\/revisions\/35455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media\/30662"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media?parent=25503"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_brand?post=25503"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_cat?post=25503"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_tag?post=25503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}